Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Nile Therapeutics, Inc. (NLTX) - Financial and Strategic SWOT Analysis Review

VIEWS: 4 PAGES: 33

Nile Therapeutics, Inc. (NLTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Nile Therapeutics, Inc. (Nile) is a development-stage biopharmaceutical company with focus o

More Info
  • pg 1
									         Nile Therapeutics, Inc. (NLTX) - Financial and Strategic SWOT Analysis
                                          Review
        Reference Code: GDPH62399FSA                                                                                           Publication Date: JUL 2013

          Suite 400, 4 West 4th Ave.                         Phone              +1 650 4582670                  Revenue          0.2 (million USD)
          San Mateo, CA                                      Fax                +1 415 8757075                  Net Profit       -1.89 (million USD)
          94402                                              Website            www.nilethera.com               Employees        2
                                                                                NLTX     [Over          The                      Pharmaceuticals           &
          United States                                      Exchange                                           Industry
                                                                                Counter]                                         Healthcare

       Company Overview
       Nile Therapeutics, Inc. (Nile) is a development-stage biopharmaceutical company with focus on the development of products for
       the treatment of cardiovascular diseases and other medical areas of unmet needs. The company develops rationally designed
       chimeric natriuretic peptide for the treatment of acute decompensated heart failure and other cardiovascular indications.
       Currently, Nile focuses on the development of its lead product candidate, Cenderitide (formerly CD-NP) is a chimeric natriuretic
       peptide used for the treatment of heart failure.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Nile Therapeutics, Inc., SWOT Analysis
         Darlene Horton, M.D.                Chief Executive Officer                  Strengths                              Weaknesses
         Peter M. Kash                       Director
                                                                                      Strong Intellectual Property           History of Losses
         Pedro Granadillo                    Director
                                                                                      Strategic Alliance
         Frank Litvack, M.D.                 Director
         Richard Brewer                      Chairman
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Fast Track Designation:                Uncertain R&D Outcomes
       Share Data                                                                     Cenderitide
                                                                                                                             Competitive Environment
         Nile Therapeutics, Inc.
                                                                                      Demographic Trends
        Share Price (USD) as on 15-Jul-                                  0.04
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                       -0.04        GlobalData
        Market Cap (million USD)                                            2
        Enterprise Value (million USD)                                      2
        Shares Outstanding (million)                                       43
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Aug 14, 2012         Nile Therapeutics Reports Q2 2012 Results
                                                                                      Aug 02, 2012         Nile Therapeutics Promotes Darlene Horton To
                                                                                                           CEO
                                                                                      Jun 21, 2012         Nile Therapeutics Appoints Darlene Horton As
                                                                                                           Chief Medical Officer
                                                                                      May 15, 2012         Nile Therapeutics Reports Q1 2012 Results


                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData

       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Nile Therapeutics, Inc. (NLTX) - Financial and Strategic SWOT                                                                  Reference Code: GDPH62399FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 3
          List of Figures ................................................................................................................................................................................. 3
       Section 1 - About the Company.......................................................................................................................................................... 4
       Nile Therapeutics, Inc. - Key Facts..................................................................................................................................................... 4
       Nile Therapeutics, Inc. - Key Employees ............................................................................................................................................ 5
       Nile Therapeutics, Inc. - Key Employee Biographies .......................................................................................................................... 6
       Nile Therapeutics, Inc. - Major Products and Services ....................................................................................................................... 7
       Nile Therapeutics, Inc. - History ......................................................................................................................................................... 8
       Nile Therapeutics, Inc. - Company Statement .................................................................................................................................. 10
       Nile Therapeutics, Inc. - Locations And Subsidiaries ....................................................................................................................... 12
          Head Office ................................................................................................................................................................................... 12
          Other Locations & Subsidiaries ..................................................................................................................................................... 12
       Section 2 – Company Analysis ......................................................................................................................................................... 13
       Nile Therapeutics, Inc. - Business Description ................................................................................................................................. 13
       Nile Therapeutics, Inc. - Corporate Strategy .................................................................................................................................... 14
       Nile Therapeutics, Inc. - SWOT Analysis.......................................................................................................................................... 15
          SWOT Analysis - Overview........................................................................................................................................................... 15
          Nile Therapeutics, Inc. - Strengths ................................................................................................................................................ 15
             Strength - Strong Intellectual Property ...................................................................................................................................... 15
             Strength - Strategic Alliance ...................................................................................................................................................... 15
             Strength - Lead Product Candidate: Cenderitide ....................................................................................................................... 15
          Nile Therapeutics, Inc. - Weaknesses .......................................................................................................................................... 15
             Weakness - History of Losses ................................................................................................................................................... 15
          Nile Therapeutics, Inc. - Opportunities .......................................................................................................................................... 16
             Opportunity - Fast Track Designation: Cenderitide ................................................................................................................... 16
             Opportunity - Demographic Trends ........................................................................................................................................... 16
             Opportunity - Market Potential – Cardiovas
								
To top